DK1141014T3 - Insulinlignende vækstfaktor (IGF) i mutantvariant - Google Patents

Insulinlignende vækstfaktor (IGF) i mutantvariant

Info

Publication number
DK1141014T3
DK1141014T3 DK00901397T DK00901397T DK1141014T3 DK 1141014 T3 DK1141014 T3 DK 1141014T3 DK 00901397 T DK00901397 T DK 00901397T DK 00901397 T DK00901397 T DK 00901397T DK 1141014 T3 DK1141014 T3 DK 1141014T3
Authority
DK
Denmark
Prior art keywords
igf
insulin
growth factor
mutant variant
mutant
Prior art date
Application number
DK00901397T
Other languages
English (en)
Inventor
Yves Dubaquie
Paul J Fielder
Henry B Lowman
Deborah L Mortensen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1141014T3 publication Critical patent/DK1141014T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK00901397T 1999-01-06 2000-01-05 Insulinlignende vækstfaktor (IGF) i mutantvariant DK1141014T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11501099P 1999-01-06 1999-01-06
US17026199P 1999-12-09 1999-12-09
PCT/US2000/000199 WO2000040613A1 (en) 1999-01-06 2000-01-05 Insulin-like growth factor (igf) i mutant variants
EP00901397A EP1141014B1 (en) 1999-01-06 2000-01-05 Insulin-like growth factor (igf) i mutant variant

Publications (1)

Publication Number Publication Date
DK1141014T3 true DK1141014T3 (da) 2005-04-11

Family

ID=26812755

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00901397T DK1141014T3 (da) 1999-01-06 2000-01-05 Insulinlignende vækstfaktor (IGF) i mutantvariant

Country Status (12)

Country Link
US (3) US6403764B1 (da)
EP (1) EP1141014B1 (da)
JP (2) JP3971108B2 (da)
AT (1) ATE284415T1 (da)
AU (1) AU762351B2 (da)
CA (1) CA2356109C (da)
DE (1) DE60016560T2 (da)
DK (1) DK1141014T3 (da)
ES (1) ES2234560T3 (da)
IL (2) IL143866A0 (da)
PT (1) PT1141014E (da)
WO (1) WO2000040613A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173005B2 (en) * 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
US20020143725A1 (en) * 2001-01-29 2002-10-03 Smith Robin Young Systems, methods and computer program products for determining parameters for chemical synthesis and for supplying the reagents, equipment and/or chemicals synthesized thereby
US7250950B2 (en) * 2001-01-29 2007-07-31 Symyx Technologies, Inc. Systems, methods and computer program products for determining parameters for chemical synthesis
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1838736B1 (en) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
JP4988599B2 (ja) * 2005-01-07 2012-08-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｇｆ−１融合ポリペプチドおよびその治療的使用
TWI406870B (zh) * 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
KR101459789B1 (ko) * 2006-06-09 2014-11-07 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP4958975B2 (ja) * 2006-08-31 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー インスリン様増殖因子ｉの製造方法
CN106908603B (zh) 2007-01-25 2019-04-02 霍夫曼-拉罗奇有限公司 Igfbp-7在心力衰竭评估中的用途
AU2008223541B2 (en) * 2007-03-02 2012-04-05 Amgen Inc. Methods and compositions for treating tumor diseases
CA2689549A1 (en) * 2007-06-08 2008-12-18 Massachusetts Institute Of Technology Igf for the treatment of rett syndrome and synaptic disorders
JP5173018B2 (ja) * 2008-04-03 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用
US20110045510A1 (en) * 2008-04-03 2011-02-24 Kurt Lang Pegylated insulin-like-growth-factor assay
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
WO2011011072A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59
US8906231B2 (en) 2009-09-10 2014-12-09 Lonza Biologics Plc Method and system for polypeptide purification
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US9676849B2 (en) 2012-01-10 2017-06-13 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
PL2935320T3 (pl) 2012-12-18 2020-03-31 Novartis Ag Stabilizowane polipeptydy insulinopodobnego czynnika wzrostu
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
CN104293766A (zh) * 2013-07-15 2015-01-21 四川农业大学 山羊IGFBP3基因cDNA编码序列克隆的方法
US20160271265A1 (en) 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
CN105992951A (zh) 2014-01-27 2016-10-05 诺华股份有限公司 预测肌萎缩的生物标志物、方法和用途
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
US11077132B2 (en) 2015-02-04 2021-08-03 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
KR102629006B1 (ko) 2017-03-23 2024-01-25 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
CN117384275B (zh) * 2023-12-13 2024-03-15 北京科为博生物科技有限公司 胰岛素样生长因子突变体igf1m及其应用

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
ATE81779T1 (de) 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
EP0288451B1 (en) 1987-04-23 1994-08-10 Monsanto Company Secretion of insulin-like growth factor 1 in E. coli
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
ATE116335T1 (de) * 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
EP0327503B1 (en) 1988-02-05 1993-03-10 Ciba-Geigy Ag Use of igf i in the manufacture of a medicament for the treatment of renal diseases
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2007886A1 (en) 1989-01-17 1990-07-17 Marvin L. Bayne Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
ZA9010332B (en) 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
TW267102B (da) 1992-03-13 1996-01-01 Ciba Geigy
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
HU217543B (hu) 1992-06-12 2000-02-28 Albert Einstein College Of Medicine Of Yeshiva University Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
ATE148710T1 (de) * 1992-12-02 1997-02-15 Hoechst Ag Verfahren zur gewinnung von proinsulin mit korrekt verbundenen cystinbrücken
CA2132871A1 (en) 1993-01-25 1994-08-04 Alan C. Moses Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
WO1994016723A2 (en) 1993-01-29 1994-08-04 Synergen, Inc. Wound healing composition
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
WO1995017423A1 (en) 1993-12-23 1995-06-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU683121B2 (en) 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5444047A (en) 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
SE9402331D0 (sv) 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
HRP940432B1 (en) 1994-08-05 2003-10-31 Pliva Pharm & Chem Works Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
US5728676A (en) 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
BRPI9608799B8 (pt) 1995-05-26 2019-11-05 Theratechnologies Inc análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
AU6046696A (en) 1995-06-07 1996-12-30 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6083913A (en) 1995-06-07 2000-07-04 Glaxo Wellcome Inc. Peptides and compounds that bind to a thrombopoietin receptor
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
CA2224859A1 (en) 1996-04-17 1997-10-23 Amitabh Gaur Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
WO1998011913A1 (en) 1996-09-16 1998-03-26 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
WO1998020036A1 (en) 1996-11-06 1998-05-14 Genentech, Inc. Constrained helical peptides and methods of making same
EP0965596A1 (en) 1996-12-27 1999-12-22 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
AU3548999A (en) 1998-04-03 1999-10-25 Chiron Corporation Use of igfi for treating articular cartilage disorders
ATE303159T1 (de) 1998-10-02 2005-09-15 Celtrix Pharma Null igf zur krebsbehandlung
WO2000023469A2 (en) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
JP2002535967A (ja) * 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
CA2372393A1 (en) 1999-05-19 2000-11-23 Bassil I. Dahiyat Novel proteins with insulin-like activity useful in the treatment of diabetes
EP2043676A2 (en) 2006-07-06 2009-04-08 Molecular Logix, Inc. Insulin-like growth factor-1 receptor antagonists

Also Published As

Publication number Publication date
AU762351B2 (en) 2003-06-26
PT1141014E (pt) 2005-04-29
IL143866A0 (en) 2002-04-21
EP1141014B1 (en) 2004-12-08
US20110003746A1 (en) 2011-01-06
US20020160955A1 (en) 2002-10-31
EP1141014A1 (en) 2001-10-10
US8097587B2 (en) 2012-01-17
IL143866A (en) 2009-11-18
AU2224500A (en) 2000-07-24
US6403764B1 (en) 2002-06-11
DE60016560D1 (de) 2005-01-13
DE60016560T2 (de) 2005-12-15
JP2002535968A (ja) 2002-10-29
ES2234560T3 (es) 2005-07-01
JP2006328074A (ja) 2006-12-07
JP3971108B2 (ja) 2007-09-05
CA2356109A1 (en) 2000-07-13
WO2000040613A9 (en) 2001-05-17
WO2000040613A1 (en) 2000-07-13
US7105167B2 (en) 2006-09-12
ATE284415T1 (de) 2004-12-15
CA2356109C (en) 2008-04-22

Similar Documents

Publication Publication Date Title
DK1141014T3 (da) Insulinlignende vækstfaktor (IGF) i mutantvariant
ATE335813T1 (de) Protease varianten
DK1141015T3 (da) Insulin-lignende vækstfaktor (IGF) I-mutantvarianter
AUPP051497A0 (en) Antimicrobial peptides
BR9811187A (pt) Composições detergentes compreendendo uma mananase e uma protease
IL143346A0 (en) Analogues of glp-1
IL143481A0 (en) Glp-1 analogues
MX9605357A (es) Variantes de subtilisina bpn' que tiene absorcion reducida e hidrolisis incrementada.
MX353234B (es) Variantes de polipeptidos con función efectora alterada.
AU2373400A (en) Shelf-stable formulation of glucagon-like peptide-1
NO20025893D0 (no) Veksthormon sekretagoga
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
MXPA02012203A (es) Analogos de peptido 1 tipo glucagon.
DK1653989T3 (da) Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel
BR9407502A (pt) Variantes subtilisina bpn com adsorção diminuída e hidrólise aumentada
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
UA50808C2 (uk) Композиція для лікування респіраторного дистрес-синдрому дорослих або респіраторного дистрес-синдрому новонароджених
LT99131A (en) Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, acitivity
ES2180948T3 (es) Peptido que proviene de una forma soluble de la acetilcolinesterasa, activo como modulador del canal.
ATE210149T1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
ID28463A (id) KOMPOSISI DENGAN KEMURNIAN TINGGI YANG TERDIRI DARI (7α, 17α)-17-HIDROKSI-7-METIL-19-NOR-17-PREGN-5(10)-EN-20-IN-3-ON
NO971508L (no) Analoger av sur fibroblastvekstfaktor med forökt stabilitet og biologisk aktivitet
PL351140A1 (en) Lyophilisates with improved reconstitutibility
EP1074264A4 (en) NEOVASCULARIZATION INHIBITORS
MY123805A (en) Stabilized pharmaceutical composition based on quinupristine and dalfopristine and their preparation.